👉PDSB is TODAY’S #1 ALERT*

Hey Folks, Jeff Bishop here,

Markets have drifted higher this week, with investors optimistic about today’s unemployment data and next week’s inflation data.

But while the major indexes have made only modest gains, the idea at the top of my “tactical” radar has soared.

💥Take a look at PDS Biotechnology Corporation (PDSB) on your trading platform.*

The stock has been on a rollercoaster ride since November, but it has kicked off 2026 with a huge 29% runup.

That included a strong 4% jump yesterday.

The stock is now sitting just below a critical level. Because it’s listed on the Nasdaq, it must meet the minimum bid price requirement…

That means it cannot close below $1.00 for 30 consecutive business days, or it could be considered delinquent.

As a result, I’ve noticed that companies (and dedicated investors) fight like heck to get their stocks above that level — and ideally keep them there!

With PDSB closing at $0.9933 yesterday, I’m watching for a big push today to get the stock back in the “safe zone”.

👉  PDSB is TODAY’S #1 ALERT* 👈

For context, PDSB is a clinical-stage immunotherapy company developing next-gen cancer treatments using its proprietary Versamune platform to leverage the immune system to fight tumors.

Its lead candidate, PDS0101 (Versamune® HPV), is moving through pivotal trials, and on December 2, the company announced it had locked in a Type C meeting with the FDA to discuss accelerated approval pathways.

Here are the top 5 things to know:

1) Elite-tier validation for lead candidate 🤝

PDSB has teamed up with some of the most respected cancer research institutions in the country…

Merck, MD Anderson Cancer Center, the National Cancer Institute, and the Mayo Clinic are all actively involved in PDSB’s programs.

Merck is supplying KEYTRUDA® for combination studies with PDS0101, while MD Anderson, NCI, and Mayo are running investigator-led and federally backed trials exploring PDSB’s immunotherapy in some of the hardest-to-treat HPV-driven cancers.

Partnerships like this happen only when a drug candidate is showing incredible promise, and that bodes well for PDSB.

2) Clinical results are turning heads 📊

In August, PDSB revealed that its flagship immunotherapy, PDS0101 (brand name Versamune® HPV), delivered very impressive survival numbers in a Phase 2 study (VERSATILE-002)…

Median overall survival was 39.3 months versus 17.9 months expected with standard of care in HPV16-positive head and neck cancer. That’s more than double.

A Phase 3 randomized trial (VERSATILE-003) is currently underway for head and neck cancer, in addition to a Phase 2 metastatic colorectal cancer study led by the National Cancer Institute and several others:

PDSB’s pipeline.

3) Building a global moat with patents 💡

On December 9, PDSB announced it had secured a new patent in Japan on its PDS0101 immunotherapy, extending intellectual property protection into the 2040s.

Patents are the backbone of biotech value — they’re what keep Big Pharma from scooping your innovation and giving you zero royalties. PDSB now says it has a “robust intellectual property position.”

4) Talks with the FDA about accelerated approval 🍿

As mentioned, PDSB recently revealed it got the FDA to agree to a Type C meeting, which is basically a sit-down to explore accelerated approval pathways for their lead candidate.

The company wants to change the Phase 3 endpoints to something the agency can review sooner (like Progression-Free Survival), potentially short-circuiting the traditional long road to approval.

The FDA has already granted PDSB’s lead candidate a Fast Track Designation. This Type C meeting could take things to the next level.

5) Wall Street is taking notice 📈 

In December, PDSB just got a Zacks upgrade to Buy, and the company’s recent earnings showed a narrower-than-expected loss with analysts adjusting estimates upward.

The company also presented multiple abstracts at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC )Annual Meeting, showing growing traction within the scientific community for not just PDS0101 but also the PDS01ADC antibody-drug conjugate platform.

Final Thoughts

As you do your own research on PDSB, near the bottom of this page you can find a short video that shows PDS0101’s mechanism of action.

You may also want to review the rest of the company’s website and its August 2025 investor presentation.

And of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from PDS Biotech Corporation (via Viruts Media) for advertising PDS Biotech Corporation for a one day marketing program starting on January 9, 2026.

It might seem obvious, but while our client claims not to own any shares in PDS Biotech Corporation, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into PDS Biotech Corporation might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.